mAIbe and LenioBio are pleased to announce a new strategic collaboration aimed at accelerating the discovery and experimental validation of next-generation monoclonal antibodies.

By combining mAIbe's AI-driven platform for antibody design and optimization with LenioBio's cell-free expression technology, this partnership brings together two complementary strengths to significantly enhance the design–build–test cycle.

LenioBio's ultrafast, scalable expression system enables rapid production of complex antibodies, providing high-quality experimental data that feeds directly into mAIbe's AI models.

Through this integrated approach, the two teams will jointly:

• accelerate functional testing of AI-generated antibody candidates
• increase the efficiency and throughput of early validation
• enable faster iteration between computational predictions and experimental results

Together, mAIbe and LenioBio set a new standard for speed, flexibility, and data-driven innovation in therapeutic antibody discovery by closing the lab-in-loop gap.